RNA-dependent RNA polymerase (RdRp) is highly conserved among coronaviruses, making RdRp inhibitors promising broad-spectrum antiviral targets for SARS-CoV-2.
RdRp inhibitors, particularly nucleoside analogs, represent a promising broad-spectrum antiviral strategy against SARS-CoV-2 due to the highly conserved nature of the RdRp enzyme.
The global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), named coronavirus disease 2019, has infected more than 8.9 million people worldwide. This calls for urgent effective therapeutic measures. RNA-dependent RNA polymerase (RdRp) activity in viral transcription and replication has been recognized as an attractive target to design novel antiviral strategies. Although SARS-CoV-2 shares less genetic similarity with SARS-CoV (~79%) and Middle East respiratory syndrome coronavirus (~50%), the respective RdRps of the three coronaviruses are highly conserved, suggesting that RdRp is a good broad-spectrum antiviral target for coronaviruses. In this review, we discuss the antiviral potential of RdRp inhibitors (mainly nucleoside analogs) with an aim to provide a comprehensive account of drug discovery on SARS-CoV-2.
Wang et al. (Tue,) conducted a review in SARS-CoV-2 (Coronavirus disease 2019). RdRp inhibitors (nucleoside analogs) was evaluated. RNA-dependent RNA polymerase (RdRp) is highly conserved among coronaviruses, making RdRp inhibitors promising broad-spectrum antiviral targets for SARS-CoV-2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: